1. Home
  2. SGHT vs DOMO Comparison

SGHT vs DOMO Comparison

Compare SGHT & DOMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGHT
  • DOMO
  • Stock Information
  • Founded
  • SGHT 2011
  • DOMO 2010
  • Country
  • SGHT United States
  • DOMO United States
  • Employees
  • SGHT N/A
  • DOMO N/A
  • Industry
  • SGHT Medical Specialities
  • DOMO Computer Software: Prepackaged Software
  • Sector
  • SGHT Health Care
  • DOMO Technology
  • Exchange
  • SGHT Nasdaq
  • DOMO Nasdaq
  • Market Cap
  • SGHT 304.4M
  • DOMO 286.1M
  • IPO Year
  • SGHT 2021
  • DOMO 2018
  • Fundamental
  • Price
  • SGHT $3.76
  • DOMO $9.98
  • Analyst Decision
  • SGHT Buy
  • DOMO Hold
  • Analyst Count
  • SGHT 6
  • DOMO 5
  • Target Price
  • SGHT $6.80
  • DOMO $9.60
  • AVG Volume (30 Days)
  • SGHT 241.4K
  • DOMO 220.6K
  • Earning Date
  • SGHT 11-07-2024
  • DOMO 12-05-2024
  • Dividend Yield
  • SGHT N/A
  • DOMO N/A
  • EPS Growth
  • SGHT N/A
  • DOMO N/A
  • EPS
  • SGHT N/A
  • DOMO N/A
  • Revenue
  • SGHT $79,543,000.00
  • DOMO $318,369,000.00
  • Revenue This Year
  • SGHT $2.18
  • DOMO $0.39
  • Revenue Next Year
  • SGHT $8.14
  • DOMO N/A
  • P/E Ratio
  • SGHT N/A
  • DOMO N/A
  • Revenue Growth
  • SGHT N/A
  • DOMO 0.19
  • 52 Week Low
  • SGHT $2.58
  • DOMO $6.11
  • 52 Week High
  • SGHT $8.45
  • DOMO $12.23
  • Technical
  • Relative Strength Index (RSI)
  • SGHT 34.38
  • DOMO 73.29
  • Support Level
  • SGHT $3.86
  • DOMO $9.14
  • Resistance Level
  • SGHT $4.11
  • DOMO $9.76
  • Average True Range (ATR)
  • SGHT 0.19
  • DOMO 0.32
  • MACD
  • SGHT 0.06
  • DOMO 0.05
  • Stochastic Oscillator
  • SGHT 13.75
  • DOMO 100.00

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

Share on Social Networks: